“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of unmet needs
Producing high quality affordable and accessible biologics
Financial Result
Share Capital
Press Releases
Press Kit
BSE -
NSE -
Lupin Quarter II, FY 2020 Results
Mumbai, November 6, 2019: Pharma major Lupin Limited reported its financial performance for the quarter and six months ended September 30, 2019. These results were taken on record by the Board of Directors at a meeting held in Mumbai today.
Key Financial & Performance Highlights
Commenting on the results, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, “The reported performance for the quarter was bolstered by the NCE licensing income but impacted by one-off items, adjusted for which, the operational performance was as expected. The US business has now stabilized and will grow based on ramp up of our in-line products and levothyroxine and the launch of our injectables portfolio. Markets like India continue to deliver solid growth. The next financial year is now looking very strong with important growth drivers like India, the in-line generic business in the US coupled with important launches like generic Albuterol in US and Fostair and Etanercept in Europe. Regulatory compliance remains a top organizational priority and we are making steady progress”
Consolidated Unaudited Financial Results – Quarter II, FY2020
Amount in INR m.
Particulars
Q2 FY2020
% of sales
Q1 FY2020
QoQ Growth %
Q2 FY2019
YoY Growth %
Sales
42,969
100.0%
43,558
-1.4%
38,909
10.4%
Other operating income
628
1.5%
626
1.4%
0.3%
601
4.4%
Total Revenue from operations
43,597
101.5%
44,184
101.4%
-1.3%
39,510
10.3%
Material cost
15,273
35.5%
15,500
35.6%
-1.5%
13,928
35.8%
9.7%
Gross Profit (Excl. Other operating income)
27,696
64.5%
28,058
64.4%
24,981
64.2%
10.9%
Employee cost
8,503
19.8%
8,072
18.5%
5.3%
7,938
20.4%
7.1%
Manufacturing & Other expenses
12,511
29.1%
12,009
27.6%
4.2%
12,148
31.2%
3.0%
Other Income
1,333
3.1%
722
1.7%
84.6%
2,307
5.9%
-42.0%
EBITDA
8,643
20.1%
9,325
21.4%
-7.3%
7,803
10.8%
Depreciation & Amortization
3,215
7.5%
3,171
7.3%
2,655
6.8%
21.1%
EBIT
5,428
12.6%
6,154
14.1%
-11.8%
5,148
13.2%
5.5%
Finance cost
864
2.0%
856
1.1%
738
1.9%
17.2%
PBT before exceptional item
4,564
10.6%
5,298
12.2%
-13.9%
4,410
11.3%
3.5%
Exceptional items(1)
5,465
12.7
PBT after exceptional items
-901
-2.1%
Current tax
549
1,816
1,843
Deferred tax
-206
464
-114
Tax
343
0.8%
2,280
5.2%
1,729
(+) Share of Profit from Joint Controlled entity
9
10
4
(-) Non-Controlling Interest
36
-3
25
Net Profit after exceptional items
-1,271
-3.0%
3,031
7.0%
2,660
Add: Exceptional items (net off tax)
3,853
Net Profit before exceptional items
2,582
6.0%
-14.8%
-2.9%
(1)Exceptional items include:
Income Statement highlights – Q2 FY2020
Balance Sheet highlights
Sales Mix
QoQ growth %
YoY growth %
Formulations
38,476
40,069
-4.0%
35,562
8.2%
North America
13,244
15,412
-14.1%
12,487
6.1%
India
13,419
13,077
2.6%
12,032
11.5%
APAC
6,352
6,717
-5.4%
6,199
2.4%
EMEA
3,196
2,604
22.7%
2,949
8.3%
LATAM
1,445
1,550
-6.8%
1,459
-1.0%
ROW
820
709
15.7%
436
88 2%
API
3,052
3,489
-12.5%
3,347
-8.7%
NCE Licensing income
1,441
Total
Operational Highlights
Lupin’s North America sales for Q2 FY2020 were INR 13,244 m. compared to sales of INR 15,412 m. during Q1 FY2020 and INR 12,487 m. during Q2 FY2019; accounting for 31% of Lupin’s global sales.
Lupin’s India formulation sales for Q2 FY2020 were INR 13,419 m. compared to sales of INR 13,077 m. during Q1 FY2020 and INR 12,032 m. during Q2 FY2019; accounting for 31% of Lupin’s global sales.
Lupin is the 6th largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2019).
Asia-Pacific (APAC)
Lupin’s APAC sales were INR 6,352 m. for Q2 FY2020 compared to sales of INR 6,717 m. during Q1 FY2020 and INR 6,199 m. during Q2 FY2019; accounting for 15% of Lupin’s global sales.
Lupin’s Japan sales were JPY 7,788 m. for Q2 FY2020 compared to JPY 8,858 m. during Q1 FY2020 and JPY 8,151 m. in Q2 FY2019.
Lupin is the 5th largest generic player in Japan (IQVIA MAT September 2019).
Lupin’s Philippines sales were PHP 448 m. during Q2 FY2020 compared to PHP 323 m. during Q1 FY2020 and PHP 383 m. during Q2 FY2019.
Europe, Middle-East and Africa (EMEA)
Lupin’s EMEA sales were INR 3,196 m. for Q2 FY2020, up 22.7% compared to sales of INR 2,604 m. during Q1 FY2020, up 8.3% as compared to sales of INR 2,949 m. during Q2 FY2019; accounting for 8% of Lupin’s global sales.
Lupin’s South Africa sales were ZAR 307 m. for Q2 FY2020 compared to ZAR 250 m. during Q1 FY2020 and
ZAR 283 m. during Q2 FY2019.
Lupin is the 3rd largest generic player in the South African market by prescription (IQVIA September 2019).
Lupin’s Germany sales were EUR 9.6 m. for Q2 FY2020 compared to EUR 7.8 m. during Q1 FY2020 and
EUR 7.3 m. during Q2 FY2019.
Latin America (LATAM)
Lupin’s LATAM sales were INR 1,445 m. for Q2 FY2020 compared to INR 1,550 m. during Q1 FY2020 and
INR 1,459 m. during Q2 FY2019; accounting for 3% of Lupin’s global sales.
Lupin’s Brazil sales were BRL 45 m. for Q2 FY2020 compared to BRL 47 m. during Q1 FY2020 and BRL 42 m. during Q2 FY2019.
Lupin’s Mexico sales were MXN 167 m. for Q2 FY2020 compared to MXN 167 m. during Q1 FY2020 and
MXN 164 m. during Q2 FY2019.
Global API
Lupin’s Global API sales were INR 3,052 m. for Q2 FY2020 as compared to INR 3,489 m. during Q1 FY2020 and INR 3,347 m. during Q2 FY2019, accounting for 7% of Lupin’s global sales.
Research and Development
Revenue Expenditure on R&D during Q2 FY2020 amounted to INR 4,356 m. (10.1% of sales) as against INR 3,785 m.( 8.7% of sales) during Q1 FY2020 and INR 3,758 m.,(9.7% of sales) for Q2 FY2019.
Lupin received approvals for 4 ANDA from the US FDA during the quarter. Cumulative ANDA filings with the US FDA stood at 427 as of September 30, 2019, with the company having received 274 approvals to date.
The Company now has 40 First-to-Files (FTF) filings including 14 exclusive FTF opportunities. Cumulative DMF filings stands at 205 as of September 30, 2019.
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact –
Arvind Bothra
Head – Investor Relations / Corporate Communications
Ph: +91-22 6640 8237
Email: arvindbothra@lupin.com